Mosys Downgraded by Zacks to Neutral (MOSY)

Share on StockTwits

Zacks cut shares of Mosys (NASDAQ: MOSY) to a neutral rating in a research note issued to investors on Thursday, AnalystRatingsNetwork reports. The firm currently has $4.60 price target on the stock.

Mosys (NASDAQ: MOSY) traded down 0.45% on Thursday, hitting $4.46. Mosys has a 1-year low of $2.76 and a 1-year high of $4.97. The stock’s 50-day moving average is currently $4.44. The company’s market cap is $180.7 million.

Several other analysts have also recently commented on the stock. Analysts at Roth Capital initiated coverage on shares of Mosys in a research note to investors on Tuesday, June 4th. They set a buy rating on the stock. Separately, analysts at Feltl & Co. initiated coverage on shares of Mosys in a research note to investors on Tuesday, March 26th. They set a buy rating and a $6.50 price target on the stock. Finally, analysts at Benchmark Co. reiterated a buy rating on shares of Mosys in a research note to investors on Tuesday, March 19th.

One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $5.55.

MoSys, Inc. (NASDAQ: MOSY) together with its subsidiaries designs, develops, markets and licenses embedded memory intellectual property (IP), used by the semiconductor industry and electronic product manufacturers.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

FireEye Shares Drop Prior to Opening Bell on CFO Departure
FireEye Shares Drop Prior to Opening Bell on CFO Departure
Goodyear Profit Exceeds Estimates on Demand in North America
Goodyear Profit Exceeds Estimates on Demand in North America
Allergen Bid Might Be Better for Teva
Allergen Bid Might Be Better for Teva
Biogen Slashes Forecast on Weakness of Tecfidera
Biogen Slashes Forecast on Weakness of Tecfidera
Whirlpool Profit for the Quarter Drops on Strong Dollar
Whirlpool Profit for the Quarter Drops on Strong Dollar
Morgan Stanley Revenue Helps It Beat the Street
Morgan Stanley Revenue Helps It Beat the Street


Advertisement
Advertisement
© 2006-2015 Ticker Report. Google+.